|Articles|December 14, 2022
PHASTAR Joins Oncology Development Program (ODP2)
Targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets.
Advertisement
PHASTAR, has joined Lean Life Science’s Oncology Development Program (ODP2). The targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
Read more about the program
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Is Artificial Intelligence Coming for Clinical Research?
2
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
3
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
4
FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
